Home
overview
Stroke is the No. 3 killer in the US and, with the ageing population of the western world, cases are on the increase. Although significant progress has been made in the prevention and treatment of stroke, mortality rates have not seen significant decreases. Over the last decade a lot has been learnt from clinical trials but there is still a long way to go and many obstacles to be overcome.

This conference will provide an opportunity for leading experts to present and discuss the most up-to-date developments and to share ideas of how the speed of progress in this field can be advanced. While t-PA therapy for the treatment of acute ischaemic stroke has now seen some success, the primary and secondary prevention of stroke remains vital. Treatments such as anti-platelet therapy for secondary prevention are now quite well established but the scope for preventative therapeutic strategies presents exciting opportunities for the future.

This event will keep you informed of the very latest on the diagnosis, monitoring, imaging, drug discovery and development for the prevention and treatment of stoke and related disorders.

A unique opportunity to learn from leading industry experts including:

· Dr Michael Bozik, Vice President, Clinical Development, Bristol-Myers Squibb
· Dr Michael O’Neill, Team Leader, Eli Lilly
· Dr Itzchak Angel, Vice President, Research & Development, D-Pharm
· Dr Mariola Soehngen, Managing Director & Chief Medical Officer, PAION
· Dr Paul Martin, Senior Clinical Scientist, Centocor
· Dr Tammy Dellovade, Senior Scientist, Curis
· Dr Bobby Sandage, Executive Vice President, Research & Development, Indevus Pharmaceuticals
· Dr Armin Schneider, Director, Molecular Neurology, Axaron Bioscience
· Ole Graff, Medical Director, Neurosearch

Benefits of Attending:
· DRUG SCREENING – Learn how new technologies are enhancing the screening of potential neuroprotective drugs
· EARLY TREATMENT OF STROKE – Evaluate the current treatment methods
· CLINICAL TRIALS – Learn why recent clinical trials have failed, how to learn from the mistakes and improve future trials
· NEUROPROTECTION – Discover which small molecules are being used to prevent neural damage in the days and weeks after stroke
· NEURON REGENERATION – Gain an insight into how these promising drugs and technologies are enhancing recovery after stroke

“I have attended SMi conferences in the past and found them very well organised and informative”
Vice President, Cephalon, March 2002

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Professor Charles Wolfe

Professor Charles Wolfe, Professor, Public Medicine, Stroke Specialist, King’s College London

9:10 THE IMPACT OF STROKE AND STROKE CARE

Professor Charles Wolfe

Professor Charles Wolfe, Professor, Public Medicine, Stroke Specialist, King’s College London

9:25 STROKE TRIAL DESIGN

Marie Luby

Marie Luby, Director, CNS Program, Perceptive Informatics

  • Imaging based inclusion and exclusion criteria – review of trials to date
  • Advantages and disadvantages of including imaging as criteria
  • Site vs central review responsibilities in imaging evaluation
  • Substitution of imaging for clinical criteria
  • Using imaging as a surrogate endpoint – summary of trials to date and future promise
  • 9:55 ANIMAL MODELS OF ISCHAEMIC STROKE

    Dr Michelle Brot

    Dr Michelle Brot, Study Director, CNS Biology, SkeleTech

  • Animal models of ischaemic stroke
  • Establishing proof of concept
  • Window of opportunity’ studies in rodents
  • A bridge to the clinic: behavioural assessments in stroke models
  • Gross observation
  • Motor skills
    Cognitive deficits
  • 10:35 WHY DO CLINICAL TRIALS IN STROKE FAIL?

    Dr Ole Graff

    Dr Ole Graff, Medical Director, Neurosearch

  • Why clinical trials fail
  • Important factors to be considered in trial design
  • The importance of a good patient select
  • Maximising the chance in each phase
  • How to spot RCT flaws early on
  • Examples of badly designed trials and how they could have been improved
  • 11:15 Morning Coffee

    11:35 PANEL DISCUSSION

    Dr Ole Graff

    Dr Ole Graff, Medical Director, Neurosearch

    Dr Michelle Brot

    Dr Michelle Brot, Study Director, CNS Biology, SkeleTech

    Marie Luby

    Marie Luby, Director, CNS Program, Perceptive Informatics

    12:15 CITICOLINE

    Dr Bobby Sandage

    Dr Bobby Sandage, Executive Vice President, Research & Development, Indevus Pharmaceuticals

  • Mechanism(s) of action
  • Preclinical safety and efficacy
  • Clinical evidence of effectiveness
  • Benefits and risks
  • Current development status
  • 12:55 Networking Lunch

    14:15 DESMOTEPLASE IN STROKE

    Dr Mariola Soehngen

    Dr Mariola Soehngen, Managing Director & Chief Medical Officer, PAION

  • Desmoteplase - a unique plasminogen activator
  • Targeted trials vs megatrials
  • The 9h time window is feasible
  • What’s next?
  • 14:55 REOPRO (ABCIXIMAB) IN ACUTE ISCHAEMIC STROKE

    Dr Paul Martin

    Dr Paul Martin, Senior Clinical Scientist, Centocor

  • The action of ReoPro in blocking platelet aggregation
  • Prevention of ischaemic events during and following percutaneous coronary intervention
  • Role of ReoPro in improving epicardial flow, microcirculation, myocardrial salvage
  • Extending treatment options beyond tPA’s 3 hour window
  • Results from the most recent safety/efficacy trials
  • 15:35 Erythropoietin: A promising neuroprotective approach to human stroke

    Prof Hannelore Ehrenreich

    Prof Hannelore Ehrenreich, Head, Clinical Neuroscience Laboratory, Max Planck Institute

  • Neuroprotection
  • NIH Stroke Scale
  • MR Imaging
  • S100B
  • Hematocrit
  • Multicenter Trial
  • 16:15 Chairman’s Closing Remarks Followed by Afternoon Tea. Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Jean-Claude Baron

    Prof Jean-Claude Baron, Consultant Neurologist & Professor, Stroke Medicine, University of Cambridge

    9:10 BRAIN TISSUE IN ISCHAEMIC STROKE

    Prof Jean-Claude Baron

    Prof Jean-Claude Baron, Consultant Neurologist & Professor, Stroke Medicine, University of Cambridge

  • Imaging the ischaemic penumbra and the role of reperfusion
  • Pathophysiological heterogeneity of acute stroke: implications for trials
  • Secondary tissue damage and clinical deterioration after stroke
  • Imaging selective neuronal loss and inflammation in the reperfused penumbra
  • Spatially remote synaptic disruption after stroke
  • Imaging plasticity, redistribution of function and reorganisation after stroke: role in recovery
  • 9:40 SIGNALLING PATHWAYS IN NEURONAL DEATH

    Dr Michael O’Neill

    Dr Michael O’Neill, Team & Project Leader, Discovery Neuroscience,, Eli Lilly

  • Identification of cell death preventing pathways
  • What are the main culprits in neuronal death?
  • Important gene expression patterns
  • Models used in the study of neuronal death
  • Drugs involved in preventing nerve death
  • 10:20 ION CHANNELS AND NEUROPROTECTION

    Dr Michael Bozik

    Dr Michael Bozik, Vice President, Clinical Development, Bristol-Myers Squibb

  • Endogenous neuroprotective responses
  • Leveraging the electrophysiology of maxi-K channels
  • MaxiPostTM in models of stroke and TBI
  • Lessons learned from the POST trials
  • Next steps in ion channel neuroprotection
  • 11:00 Morning Coffee

    11:20 BIVALENT METAL IONS IN NEURODEGENERATION

    Dr Itzchak Angel

    Dr Itzchak Angel, Vice President, R&D, D-Pharm

  • Role of metal ion in neuronal death
  • Association between metal ions and cerebral ischaemia
  • Activation of matrix metalloperoteinases and their consequences in the ischaemic cascade
  • Effectiveness of calcium and zinc sparing mechanisms in reducing damage
  • Trial results of metal ion chelators to date
  • 12:00 AX200: A NOVEL NEUROPROTECTIVE CONCEPT IN STROKE

    Dr Armin Schneider

    Dr Armin Schneider, Director, Molecular Neurology, Axaron Bioscience

  • Mechanism(s) of action
  • Current status
  • Current plans
  • 12:40 Networking Lunch

    14:00 HEDGEHOG PATHWAY IN ACUTE ISCHAEMIC STROKE

    Dr Tammy Dellovade

    Dr Tammy Dellovade, Senior Scientist, Curis

  • Efficacy of small molecule Hh agonist
  • Introduction to Hh pathway
  • Development of small molecule Hh agonist
  • Efficacy of agonist in stroke model
  • Potential for long-term behavioural recovery
  • 14:40 IDENTIFICATION OF NOVEL NEUROPROTECTIVE MECHANISMS

    Dr Roman Urfer

    Dr Roman Urfer, Vice President, Drug Discovery & Development, AGY Therapeutics

  • Stroke models in neurodegeneration, neuroprotection and functional recovery
  • High-resolution temporal and spatial gene expression profiling
  • Target validation by RNA interface and classical pharmacology
  • Screen design and identification of neuroprotective compounds
  • 15:20 Afternoon Tea

    15:40 TELOMICS(TM) TECHNOLOGIES FOR SCREENING NEUROPROTECTIVE DRUGS

    Dr Cara Heers

    Dr Cara Heers, Manager, Business Development, KeyNeurotek

  • Ex vivo and in vivo technologies
  • Ex vivo stroke models
  • Ex vivo robotics
  • Effect of reference compounds in ex vivo stroke models
  • Further applications for ex vivo technologies
  • 16:20 STEM CELL THERAPIES

    Dr Paul Stroemer

    Dr Paul Stroemer, Investigator, ReNeuron

  • Potential of stem cell therapy in neural regeneration
  • Establishing genetic stability
  • How far off are stem cell therapies from mainstream use?
  • Future advances in stem cell therapies
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.